Fig. 1.

Expression levels of MEG3 and methylation related genes in different stages of CML and in healthy donors and the methylation status of MEG3 in different stages of CML and in healthy donors. A. The MEG3 mRNA level was lower in the CML-AP and CML-BP patients than that in the CML-CP patients and the healthy donors. B. The methylation of the MEG3 promoter was not detected in the normal controls. Methylation can be detected in 20% of the CML-CP samples. All CML-AP samples showed methylation of the MEG3 DNA promoter, and methylation can be detected in 100% of the CML-BP samples. C. After treatment with chidamide, the MEG3 was unmethylated in both K562 (a) and KCL22 (b) cells. D. The mRNA expressions of DNMT1, DNMT3A, DNMT3B, MBD2, MECP2, and HDAC1 in NC, CML-CP, CML-AP, and CML-BP groups were determined by RT-PCR. E. The protein levels of DNMT1, DNMT3A, DNMT3B, MBD2, MECP2, and HDAC1 in NC (n = 10), CML-CP (n = 30), CML-AP (n = 15), and CML-BP (n = 15) groups were determined. The protein expression levels were determined by immunoblotting with ACTB as a control. F. Protein expression of DNMT1 (a), DNMT3A (b), DNMT3B (c), MBD2 (d), MECP2 (e), HDAC1 (f) in the bone marrow cells from CML patients and normal controls. The one-way ANOVA was used for data analysis. *: P < 0.05 compared to NC group. **: P < 0.01 compared to NC group. #: P < 0.05 compared to CML-CP group. M, methylated; U, unmethylated.